Gilead Sciences | GILD - Ordinary Share Capital

Stock Price
139.71
Daily Change
-0.59 -0.42%
Monthly
-5.49%
Yearly
24.31%
Q2 Forecast
135.50

Gilead Sciences reported $1.24B in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
ALKERMES USD 165.61M 503K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amgen USD 539M 1000K Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
GlaxoSmithKline GBP 4.08B 49.43M Dec/2025
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
J&J USD 2.41B 584K Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novartis USD 1.91B 10.64M Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.96M 196K Dec/2025
United Therapeutics USD 43.64M 740K Dec/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025